Using the antinuclear antibody test to diagnose rheumatic diseases: When does a positive test warrant further investigation?

Southern Medical Journal

Volumn 105, Issue 2, 2012, Pages 100-104

  Volkmann, Elizabeth R ^a   Taylor, Mihaela ^a   Ben Artzi, Ami ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antinuclear antibody (ANA); rheumatic diseases; systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; IMMUNOGLOBULIN;

ANTIBODY RESPONSE; ANTIBODY TITER; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; INTERMETHOD COMPARISON; OCCULT BLOOD TEST; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PREDICTIVE VALUE; PROCESS OPTIMIZATION; PROFESSIONAL COMPETENCE; REVIEW; RHEUMATIC DISEASE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; RHEUMATIC DISEASES; SENSITIVITY AND SPECIFICITY;

EID: 84856121370     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31824551a1     Document Type: Review

References (25)

1. Holborow EJ, Asherson GL, Johnson GD, et al. Antinuclear factor and other antibodies in blood and liver diseases. Br Med J 1963;9: 65-658
2. Moore AE, Sabachewsky L, Toolan HW. Culture characteristics of four permanent lines of human cancer cells. Cancer Res 1955;15:59-602
3. Gniewek RA, Stites DP, McHugh TM, et al. Comparison of antinuclear antibody testing methods: immunofluorescence assay versus enzyme immunoassay. Clin Diagn Lab Immunol 1997;4:18-188
4. Fritzler MJ, Wiik A, Tan EM, et al. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J Rheumatol 2003;30:237-2381
5. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010;69:142-1422
6. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in ''healthy'' individuals. Arthritis Rheum 1997;40:160-1611
7. Li QZ, Karp DR, Quan J, et al. Risk factors for ANA positivity in healthy persons [published online ahead of print]. Arthritis Res Ther 2011; 13:R38
8. Lahita RG, Chiorazzi N, Gibofsky A, et al. Familial systemic lupus erythematosus in males. Arthritis Rheum 1983;26:3-44
9. Farnam J, Lavastida MT, Grant JA, et al. Antinuclear antibodies in the serum of normal pregnant women: a prospective study. J Allergy Clin Immunol 1984;73:59-599
10. Alves MF, Fraiji NA, Barbosa AC, et al. Fish consumption, mercury exposure and serum antinuclear antibody in Amazonians. Int J Environ Health Res 2006;16:25-262
11. Covini G, von Muhlen CA, Pacchetti S, et al. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol 1997;26: 125-1265
12. Timuragaoglu A, Duman A, Ongut G, et al. The significance of autoantibodies in non-Hodgkin's lymphoma. Leuk Lymphoma 2000;40: 11-122
13. Thomas PJ, Kaur JS. Antinuclear, antinucleolar and anticytoplasmic antibodies in patients with malignant melanoma. Cancer Res 1983;43: 137-1382
14. Berlin T, Zandman-Goddard G, Blank M, et al. Autoantibodies in nonautoimmune individuals during infections. Ann N Y Acad Sci 2007;1108: 58-593
15. Katz U, Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010;10:4-50
16. Bossuyt X, Hendrickx A, Frans J. Antinuclear antibody titer and antibodies to extractable nuclear antigens. Arthritis Rheum 2005;53:98-988
17. Khan S, Alvi A, Holding S, et al. The clinical significance of antinucleolar antibodies. J Clin Pathol 2008;61:28-286
18. Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Arthritis Rheum 2002;47:43-444
19. Baturone R, Soto MJ, Ma'rquez M, et al. Health-related quality of life in patients with primary Sjögren's syndrome: relationship with serum levels of proinflammatory cytokines. Scand J Rheumatol 2009;38:38-389
20. Wigley FM. Raynaud's phenomenon. N Engl JMed 2002;347:100-1008
21. Spencer-Green G. Outcomes in primary Raynaud phenomenon: a metaanalysis of the frequency, rates, and predictors of transition to secondary disease. Arch Intern Med 1998;158:59-600
22. Maricq HR, LeRoy EC. Patterns of finger capillary abnormalities in connective tissue disease by ''wide-field'' microscopy. Arthritis Rheum 1973;16:61-628
23. Wijeyesinghe U, Russell AS. Outcome of high titer antinuclear antibody positivity in individuals without connective tissue disease: a 10-year follow-up. Clin Rheumatol 2008;27:139-1402
24. Peene I, Meheus L, Veys EM, et al. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 2001;60:113-1136
25. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:152-1533.